依鲁替尼治疗患者发生肺结核风险的要点：病例报告及文献综述 - Suppr

Highlights on the risk of pulmonary tuberculosis in patients on ibrutinib treatment: Case report and literature review.

作者信息

Traoré Solo, Roumila Mehdi, Eftekhari Pirayeh, Farhat Hassan, Merabet Fatiha, Guira Oumar, Rousselot Philippe, Azarian Reza, Besson Caroline

机构信息

Training and Research Unit in Health Sciences Joseph Ki ZERBO University Ouagadougou Burkina Faso.

Department of Internal Medicine Yalgado Ouedraogo Teaching Hospital Ouagadougou Burkina Faso.

出版信息

EJHaem. 2020 Sep 19;1(2):601-603. doi: 10.1002/jha2.80. eCollection 2020 Nov.

DOI:10.1002/jha2.80

PMID:35844981

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9176077/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63aa/9176077/eabc5a2ccf3c/JHA2-1-601-g001.jpg

相似文献

Highlights on the risk of pulmonary tuberculosis in patients on ibrutinib treatment: Case report and literature review.依鲁替尼治疗患者发生肺结核风险的要点：病例报告及文献综述

EJHaem. 2020 Sep 19;1(2):601-603. doi: 10.1002/jha2.80. eCollection 2020 Nov.

Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature.依鲁替尼治疗患者的多真菌败血症和中枢神经系统毛霉菌病：一例报告及文献复习

Med Mycol Case Rep. 2019 Dec 3;27:14-16. doi: 10.1016/j.mmcr.2019.12.005. eCollection 2020 Mar.

Ibrutinib suppresses intracellular mycobacterium tuberculosis growth by inducing macrophage autophagy.伊布替尼通过诱导巨噬细胞自噬来抑制细胞内结核分枝杆菌的生长。

J Infect. 2020 Jun;80(6):e19-e26. doi: 10.1016/j.jinf.2020.03.003. Epub 2020 Mar 11.

Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.依鲁替尼相关的严重皮肤毒性：一名68岁复发慢性淋巴细胞白血病男性患者出现多处皮肤炎症性病变和蜂窝织炎的病例报告及文献综述

J Oncol Pharm Pract. 2020 Mar;26(2):487-491. doi: 10.1177/1078155219856422. Epub 2019 Jun 19.

Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.与依鲁替尼用于B细胞恶性肿瘤患者相关的独特不良事件病例系列——单机构经验及文献综述

J Oncol Pharm Pract. 2019 Jul;25(5):1265-1270. doi: 10.1177/1078155218788707. Epub 2018 Jul 25.

Ibrutinib-Associated Skin Toxicity: A Case of Maculopapular Rash in a 79-Year Old Caucasian Male Patient with Relapsed Waldenstrom's Macroglobulinemia and Review of the Literature.依鲁替尼相关的皮肤毒性：一例79岁复发性华氏巨球蛋白血症白种男性患者的斑丘疹病例及文献综述

Dermatol Reports. 2017 Apr 20;9(1):6976. doi: 10.4081/dr.2017.6976. eCollection 2017 Mar 13.

Association between ibrutinib and mid-cavitary Takotsubo cardiomyopathy: a case report and a review of chemotherapy-induced Takostubo's cardiomyopathy.依鲁替尼与心尖球形综合征的关联：一例病例报告及化疗所致心尖球形综合征的综述

Eur Heart J Case Rep. 2017 Nov 2;1(2):ytx006. doi: 10.1093/ehjcr/ytx006. eCollection 2017 Dec.

Ibrutinib-induced cardiomyopathy.依鲁替尼诱发的心肌病。

J Community Hosp Intern Med Perspect. 2019 Feb 11;9(1):50-52. doi: 10.1080/20009666.2018.1555432. eCollection 2019.

Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy.依鲁替尼相关的心包填塞合并抗血小板治疗

Case Rep Hematol. 2020 Mar 27;2020:4282486. doi: 10.1155/2020/4282486. eCollection 2020.

Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases.依鲁替尼所致严重肝毒性及已发表病例综述

Case Rep Gastroenterol. 2019 Aug 30;13(2):357-363. doi: 10.1159/000502605. eCollection 2019 May-Aug.

本文引用的文献

Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology.伊布替尼或idelalisib 治疗慢性淋巴细胞白血病患者的感染控制：意大利血液学会的建议。

Leuk Res. 2019 Jun;81:88-94. doi: 10.1016/j.leukres.2019.04.016. Epub 2019 May 2.

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼对巨噬细胞和γδT细胞介导的抗结核分枝杆菌反应的影响。

Blood Cancer J. 2018 Nov 5;8(11):100. doi: 10.1038/s41408-018-0136-x.

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.伊布替尼用于慢性淋巴细胞白血病/小淋巴细胞淋巴瘤或套细胞淋巴瘤患者的四项随机对照研究的安全性分析

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):648-657.e15. doi: 10.1016/j.clml.2018.06.016. Epub 2018 Jun 28.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.伊布替尼联合利妥昔单抗治疗华氏巨球蛋白血症的 3 期临床试验。

N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).ESCMID 研究组对免疫受损宿主感染（ESGICH）共识文件：靶向和生物治疗的安全性：传染病观点（可溶性免疫效应分子 [I]：抗肿瘤坏死因子-α制剂）

Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S10-S20. doi: 10.1016/j.cmi.2017.12.025. Epub 2018 Feb 6.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).欧洲临床微生物学和传染病学会（ESCMID）感染宿主研究组（ESGICH）关于靶向和生物治疗安全性的共识文件：传染病学视角（细胞内信号通路：酪氨酸激酶和 mTOR 抑制剂）。

Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S53-S70. doi: 10.1016/j.cmi.2018.02.009. Epub 2018 Feb 16.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52).欧洲临床微生物学和传染病学会（ESCMID）感染宿主研究组（ESGICH）关于靶向和生物治疗安全性的共识文件：传染病学视角（靶向淋巴细胞表面抗原的药物 [I]：CD19、CD20 和 CD52）。

Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S71-S82. doi: 10.1016/j.cmi.2018.02.003. Epub 2018 Feb 12.

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.依鲁替尼可改变慢性淋巴细胞白血病中单核细胞/巨噬细胞群体的功能。

Oncotarget. 2016 Oct 4;7(40):65968-65981. doi: 10.18632/oncotarget.11782.

Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia.慢性淋巴细胞白血病患者使用伊布替尼后发生粟粒性肺结核。

Ann Hematol. 2015 Aug;94(8):1419-20. doi: 10.1007/s00277-015-2385-0. Epub 2015 Apr 24.

The immune response in tuberculosis.结核的免疫反应。

Annu Rev Immunol. 2013;31:475-527. doi: 10.1146/annurev-immunol-032712-095939.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Highlights on the risk of pulmonary tuberculosis in patients on ibrutinib treatment: Case report and literature review.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献